Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
12/05/2026 12:02
May 12 (Reuters) - Alkermes Plc ALKS.O: ALKERMES ANNOUNCES POSITIVE TOPLINE RESULTS FROM REVITALYZ℠ PHASE 3 STUDY EVALUATING LUMRYZ® (SODIUM OXYBATE) EXTENDED-RELEASE IN ADULTS WITH IDIOPATHIC HYPERSOMNIA ALKERMES PLC - LUMRYZ MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTS IN REVITALYZ PHASE 3 STUDY ALKERMES PLC - LUMRYZ SAFETY PROFILE IN REVITALYZ STUDY CONSISTENT WITH KNOWN SAFETY DATA ALKERMES PLC - MAY NOT MARKET LUMRYZ FOR IH BEFORE MARCH 1, 2028 Source text: ID:nBw2SCfYja Further company coverage: ALKS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alkermes
See all newsBrief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
Brief: Alkermes Announces Effectiveness Of Mural Oncology Form 10 Registration Statement
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes Q3 Net Income USD 47.8 Million